CNA Financial Corp purchased a new stake in MEDNAX Inc (NYSE:MD) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 8,634 shares of the company’s stock, valued at approximately $461,000.
Several other institutional investors and hedge funds also recently made changes to their positions in MD. QS Investors LLC boosted its stake in shares of MEDNAX by 0.3% during the 2nd quarter. QS Investors LLC now owns 3,812 shares of the company’s stock worth $230,000 after purchasing an additional 12 shares during the last quarter. Nomura Holdings Inc. acquired a new position in MEDNAX during the second quarter valued at approximately $347,000. Verition Fund Management LLC acquired a new position in MEDNAX during the second quarter valued at approximately $516,000. Lord Abbett & CO. LLC acquired a new position in MEDNAX during the second quarter valued at approximately $14,346,000. Finally, Mutual of America Capital Management LLC lifted its position in MEDNAX by 3.2% during the third quarter. Mutual of America Capital Management LLC now owns 77,239 shares of the company’s stock valued at $3,331,000 after buying an additional 2,422 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
Shares of MEDNAX Inc (NYSE:MD) opened at $54.76 on Thursday. The stock has a market cap of $5,056.45, a P/E ratio of 17.19, a PEG ratio of 1.34 and a beta of 0.31. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.37 and a current ratio of 1.43.
A number of research analysts have weighed in on the stock. Robert W. Baird lifted their price target on shares of MEDNAX from $48.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the company a “hold” rating in a research report on Tuesday, February 6th. Stephens set a $62.00 price target on shares of MEDNAX and gave the company a “buy” rating in a research report on Thursday, February 8th. Mizuho reaffirmed a “neutral” rating and set a $53.00 price target (up from $49.00) on shares of MEDNAX in a research report on Friday, February 9th. Finally, BMO Capital Markets lifted their price target on shares of MEDNAX from $46.00 to $58.00 and gave the company a “market perform” rating in a research report on Monday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company’s stock. MEDNAX currently has an average rating of “Hold” and a consensus price target of $54.92.
In related news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares in the company, valued at $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.40% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “CNA Financial Corp Purchases New Holdings in MEDNAX Inc (MD)” was first published by Week Herald and is owned by of Week Herald. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://weekherald.com/2018/02/15/cna-financial-corp-purchases-new-holdings-in-mednax-inc-md.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.